Primco's Top Sail Productions Offers Special Discount on All of Its "Casey Kasem Presents America's Top Ten Hits" CD's

LOS ANGELES--(BUSINESS WIRE)-- Primco Management Inc. (OTCQB:PMCM), a fully integrated multimedia entertainment and real estate development company, is pleased to announce that, for a limited time, its Top Sail Productions subsidiary is offering a special 25% discount to music lovers purchasing one or more of the Casey Kasem presents America's Top Ten Hits CD series.

To claim this special discount, purchasers should visit Top Sail's dedicated website: www.AmericasTopTenHits.com. The site includes all CD collections released by the "King of Countdowns" himself, Casey Kasem. Each CD contains the greatest top ten hits from the 50's, 60's, 70's, 80's, and 90's. Choose your favorite decade(s), add the CDs to the cart, and simply type PMCM (upper case) in the Coupon Code section to automatically receive the 25% discount.

The Casey Kasem presents America's Top Ten Hits CD series is part of Top Sail Productions, a record label which was acquired by Primco/ESMG earlier this year. The Casey Kasem CD series has sold more than two million units to date and is distributed through WEA, a Warner Music Group Company.

"We are extremely pleased to be able to make this special discount offer to music lovers who enjoy the hit sounds of the 50's through the 90's available from this remarkable music catalog", stated David Michery, President and CEO, Primco Management Inc. "It will give our music fans and investors a firsthand look at the quality of our Top Sail product line as well as having the opportunity to enjoy one of the best selections of music from the pop/rock era".

About Primco Management Inc.:

Through its wholly-owned subsidiaries, ESMG Inc. and Top Sail Productions LLC, the Company operates as an integrated entertainment company with divisions in music and film production and distribution, and is launching additional divisions in television, radio and online sports. The Company also operates in various aspects of the real estate industry. Through its highly skilled and industry experienced management team, the Company provides leading edge/dynamic services and digital content to worldwide audiences. ESMG Inc. leverages its highly motivated and industry experienced management strengths and capabilities with focused operating divisions to reach and satisfy the marketplace of targeted consumers searching for a breakthrough in new and exciting talent and content. (For additional information, visit www.primcousa.com).

Disclaimer: The Company relies upon the Safe Harbor Laws of 1933, 1934 and 1995 for all public news releases. Statements, which are not historical facts, are forward-looking statements. The company, through its management, makes forward-looking public statements concerning its expected future operations, performance and other developments. Such forward-looking statements are necessarily estimates reflecting the company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. It is impossible to identify all such factors. Factors which could cause actual results to differ materially from those estimated by the company include, but are not limited to, government regulation; managing and maintaining growth; the effect of adverse publicity; litigation; competition; and other factors which may be identified from time to time in the company's public announcements.

Primco Management/ESMG, Inc. & Top Sail Productions
Alan Bailey, 310-407-5452

KEYWORDS:   United States  North America  California

INDUSTRY KEYWORDS:

Revionics and Nielsen Form Global Strategic Alliance

Joint solutions raise the bar on the precision of retail pricing

ROSEVILLE, Calif.--(BUSINESS WIRE)-- Revionics, Inc., the leading provider of End-to-End Merchandise Optimization solutions, and Nielsen Holdings, N.V. (NYS: NLSN) , a leading global provider of information and insights into what consumers watch and buy, have signed a multi-year global strategic alliance agreement which will integrate Nielsen Pricing Insights with Revionics Life Cycle Price Optimization solutions. The alliance brings together best-in-class competitive market insights with proven demand-based science and predictive analytics to help retailers quickly make data-driven pricing changes at enterprise scale to capitalize on competitive marketplace conditions.

"Our combined solutions enable retailers to answer critical questions such as the competitive position of their prices to the market, what is the price elasticity of the market, what profit opportunities exist with their pricing strategy, are they growing market share with their price and promotional strategies," stated James Dodge, Vice President, Retail Consulting & Analytics, Nielsen. "Providing answers to these questions empowers retailers to enhance competitiveness and profitability."

Today's retailers are battling intense pressures from existing competitors, format encroachment by new competitors, rising commodity costs and increasingly price-conscious, deal-seeking, knowledgeable shoppers who rapidly shift their buying behaviors. To compete more profitably, retailers need to make better strategic and tactical decisions based on marketplace and shopper analysis rather than gut feel—and respond quickly to dynamic marketplace conditions. For retailers to find success in today's price transparent world, they need to systematically leverage comprehensive market insights and optimization technologies to execute impactful price and promotion strategies in the market.

"The reality of the competitive retail landscape places intense pressure on retailers," said Kevin Sterneckert, Vice President, Research - Consumer Value Chain, Gartner. "Through the advanced analysis of consumer behavior, retailers can identify items or categories of merchandise where the consumer expects or allows flexible pricing."

Revionics Price Optimization Infused with Nielsen Pricing Insights to Offer Better Visibility into a Retailer's Competitive Pricing Environment

The initial solution, which is immediately available, integrates Revionics Price Optimization and Nielsen Pricing Insights. This combined solution provides enhanced visibility into a retailer's competitive pricing environment and Key Value Items (KVIs) at a local level. Through the alliance, Nielsen will provide Revionics with its comprehensive Nielsen Pricing Insights, which provides more granular information to show specific price points that consumers are paying and the volume sold at those price points in the competitive marketplace. Revionics Price Optimization integrates Nielsen Pricing Insights to appropriately weigh the importance of the individual prices along with other optimization engines and business rules. Revionics Price Optimization infused with Nielsen Pricing Insights will allow retailers to adapt to marketplace changes quickly and stay more competitive.

Additional solutions will be available in 2014.

"Nielsen is the leader in offering global data and insights and we are excited to be working together to empower retailers to leverage data-driven strategies and have constant intelligence about their competitive pricing environment, resulting in optimal pricing and promotion strategies," said Marc Hafner, Revionics' President and CEO. "Offering retailers superior visibility into market opportunities and their competition will help retailers substantially improve customer loyalty, profits and margins."

About Revionics, Inc.

Revionics delivers the industry's most powerful End-to-End Merchandise Optimization solution, enabling retailers of all sizes to execute a fact-based Omni-channel merchandising strategy utilizing the most comprehensive set of shopper demand signals to enhance financial performance with improved customer satisfaction. Revionics' solutions leverage advanced predictive analytics and demand-based science to ensure retailers have the right product, price, promotion, placement and space allocation for optimal results across all touch points in the Omni-channel shopping episode - online, in-store, social and mobile. Offered on a scalable, high performance Cloud-based SaaS platform, these solutions future-proof retailers from Big Data/Fast Data challenges, while providing speed-to-ROI. Over 33,000 retail locations and $140+B in annual revenue across grocery, drug, building materials, convenience, general merchandise, discount, sporting goods stores and eCommerce sites optimize with Revionics' solutions. Revionics has been recognized as a 2012 Deloitte Technology Fast 500™, Red Herring Top 100 Global, Red Herring Top 100 Americas and JMP Securities' Hot 100 Software Company. For more information, please visit www.revionics.com.

Revionics, Inc.
Karen Dutch, +1 916-865-5394 (USA)
Senior Vice President of Marketing
kdutch@revionics.com

KEYWORDS:   United Kingdom  United States  Europe  North America  California

INDUSTRY KEYWORDS:

Cancer Research Technology and Teva Pharmaceuticals Form R&D Alliance for Cancer DNA Damage Response Drugs

JERUSALEM & LONDON--(BUSINESS WIRE)-- Cancer Research Technology Ltd. (CRT), Cancer Research UK's technology development arm, and Teva Pharmaceutical Industries Ltd. (NYS: TEVA) have signed a multi-project alliance agreement to research and develop first-in-class cancer drugs that modulate DNA damage and repair response (DDR) processes in cancer cells.

DDR plays a key role in protecting cancer cells from the damaging effect of chemotherapy - creating an in-built antidote to the toxic effects of the anti-tumor drug. As the cancer cells that are best able to repair the DNA damage caused by the cancer treatments survive, they replicate, naturally selecting for the mutation with the enhanced repair capability - leading to recurrence and resistance to treatment.

Cancer Research UK and CRT has created a world-class hub of expertise in DDR-related basic, translational, and clinical research that is leading the field; building the understanding that will hopefully enable "smarter" use of this very interesting approach in the development of new treatment options.

Based on Cancer Research UK's extensive network of leading UK universities, and its five cancer research institutes (Gray Institute, Oxford; Cancer Research UK Cambridge Institute; London Research Institute; Paterson Institute, Manchester; and the Beatson Institute, Glasgow), this hub will provide the foundations for CRT's and Teva's work towards developing novel therapies based on DDR-related targets for the treatment of cancer.

"For cancer patients, it is important that we maintain the momentum of progress that has been made in oncology in recent years," said Dr. Michael Hayden, President, Teva Global R&D and Chief Scientific Officer. "Cancer Research UK, CRT, and their outstanding academic partners, are a driving force in the improved understanding of cancer and its treatment. This research collaboration will build on our understanding of how cells repair DNA damage, help us identify possible points of therapeutic intervention, and lead us onto a pathway toward improve clinical outcomes for cancer patients."

The alliance provides Teva with the opportunity to research and develop selected and differentiated novel treatments targeting DDR processes. With a focus on mechanisms and molecular targets related to the emergence of therapeutic resistance in cancer cells, the partnership also opens up the potential to expand the clinical utility and therapeutic effectiveness of Teva's current portfolio of oncology chemotherapeutic agents. This approach builds on Teva's growing focus on personalized medicine throughout its R&D pipeline, and specifically within its oncology portfolio.

Building on a prior well-established working relationship, the multi-year agreement sets out the provision of new molecular targets, selected by CRT from Cancer Research UK's portfolio of biological research in DDR. These targets will be validated to prove their therapeutic importance before progressing to the early stages of drug discovery in CRT's Discovery Laboratories. CRT and Teva will then jointly undertake chemical lead generation activities. Under the terms of the agreement, CRT will receive research funding and be eligible to receive milestone payments, and royalties on projects advancing through Teva's drug pipeline.

Dr Hamish Ryder, director of drug discovery at CRT's Discovery Laboratories, said: "Cancer Research UK scientists are carrying out exciting research in the area of DNA damage repair. Some cancer therapies work by targeting DNA damage response pathways in cancer cells, and finding new ways to block repair in tumors can boost the effectiveness of existing therapies. This exciting alliance with Teva brings together the cutting-edge research funded by Cancer Research UK, CRT's expertise in progressing new drug targets and Teva's drug research and development capabilities in a compelling partnership."

Harpal Kumar, Cancer Research UK's chief executive, said: "Our scientists are leading the world in understanding the machinery that causes and subsequently repairs damage to DNA in our cells. We believe this machinery offers many opportunities for new treatments. Cancer Research UK has been at the heart of research that has seen survival from cancer double in the last forty years. By working alongside international partners from industry to discover and develop new targeted cancer drugs we hope to be able to accelerate this progress. This innovative alliance provides a vital new route to turn our research excellence into new drugs to treat cancer patients, hopefully saving more lives, more quickly."

Notes to editors: *The alliance will span the drug discovery process - from new target validation - proving a protein's importance as a therapeutic target, though to lead optimization - synthesizing compounds for further development as potential drugs.

About Cancer Research Technology

Cancer Research Technology (CRT) is a specialist commercialization and development company, which aims to develop new discoveries in cancer research for the benefit of cancer patients. CRT works closely with leading international cancer scientists and their institutes to protect intellectual property arising from their research and to establish links with commercial partners. CRT facilitates the discovery, development and marketing of new cancer therapeutics, vaccines, diagnostics and enabling technologies. CRT is a wholly owned subsidiary of Cancer Research UK, the world's leading cancer charity dedicated to saving lives through research. Further information about CRT can be found at www.cancertechnology.com

About Cancer Research UK

Cancer Research UK is the world's leading cancer charity dedicated to saving lives through research. The charity's pioneering work into the prevention, diagnosis and treatment of cancer has helped save millions of lives. Cancer Research UK receives no government funding for its life-saving research. Every step it makes towards beating cancer relies on every pound donated. Cancer Research UK has been at the heart of the progress that has already seen survival rates in the UK double in the last forty years. Cancer Research UK supports research into all aspects of cancer through the work of over 4,000 scientists, doctors and nurses. Together with its partners and supporters, Cancer Research UK's vision is to bring forward the day when all cancers are cured. For further information about Cancer Research UK's work or to find out how to support the charity, please call 0300 123 1022 or visit www.cancerresearchuk.org. Follow us on Twitter and Facebook.

About Teva

Teva Pharmaceutical Industries Ltd. (NYS: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's leading generic drug maker, with a global product portfolio of more than 1,000 molecules and a direct presence in about 60 countries. Teva's branded businesses focus on CNS, oncology, pain, respiratory and women's health therapeutic areas, as well as biologics. Teva currently employs approximately 46,000 people around the world and reached $20.3 billion in net revenues in 2012.

Teva Pharmaceutical Industries Ltd.:
IR
United States
Kevin C. Mannix, 215-591-8912
or
Israel
Tomer Amitai, 972 (3) 926-7656
or
United States
Ran Meir, 215-591-3033
or
Media
Israel
Iris Beck Codner, 972 (3) 926-7683
or
United States
Denise Bradley, 215-591-8974
or
Cancer Research Technology
Media
United Kingdom
Emma Rigby, 020 3469 8300

KEYWORDS:   United Kingdom  Europe  Middle East  Israel

INDUSTRY KEYWORDS:

OncoSec Medical Announces $12 Million Public Offering

SAN DIEGO--(BUSINESS WIRE)-- OncoSec Medical Inc. (OTCQB:ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors, announced today that it has entered into definitive agreements with institutional investors to purchase approximately $12 million of securities in a registered public offering. OncoSec has agreed to sell to institutional investors an aggregate of 47,792,000 shares of its common stock at $0.25 per share. Additionally, investors will receive warrants to purchase up to 23,896,000 shares of common stock at an exercise price of $0.35 per share for a term of four years.

The gross proceeds of the offering are expected to be approximately $12 million. Net proceeds, after deducting the placement agent's fee and other estimated offering expenses payable by OncoSec, are expected to be approximately $11.1 million.

OncoSec intends to use proceeds from the offering for general corporate purposes, including clinical trial expenses and research and development expenses.

H.C. Wainwright & Co., LLC acted as the exclusive placement agent for the transaction. Maxim Group LLC acted as the financial advisor to OncoSec in connection with the transaction.

The offering is expected to close on or about September 19, 2013, subject to customary closing conditions.

The securities described above are being offered by OncoSec pursuant to a registration statement previously filed and declared effective by the Securities and Exchange Commission, or the SEC. A prospectus supplement related to the offering will be filed with the SEC. The securities may only be offered by means of a prospectus. Copies of the prospectus and prospectus supplement can be obtained directly from OncoSec and at the SEC's website at www.sec.gov or by request at H.C. Wainwright & Co., LLC by e-mailing placements@hcwco.com.

This announcement is neither an offer to sell nor a solicitation of an offer to buy any of OncoSec's common stock or warrants. No offer, solicitation or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.

About OncoSec Medical Inc.

OncoSec Medical Inc. is a biopharmaceutical company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors. ImmunoPulse and NeoPulse therapies address an unmet medical need and represent a potential solution, for less invasive and less expensive therapies that are able to minimize detrimental effects resulting from currently available cancer treatments such as surgery, systemic chemotherapy or immunotherapy and other treatment alternatives.

OncoSec Medical's core technology is based upon its proprietary use of an electroporation platform to enhance the delivery and uptake of a locally delivered DNA-based immunocytokine (ImmunoPulse) or chemotherapeutic agent (NeoPulse). Treatment of various solid cancers using these targeted anti-cancer agents has demonstrated selective destruction of cancerous cells while potentially sparing healthy normal tissues during early and late stage clinical trials. OncoSec's clinical programs include three Phase II clinical trials for ImmunoPulse targeting lethal skin cancers. More information is available at http://www.oncosec.com/.

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec Medical's filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec Medical disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

Investor Relations:
OncoSec Medical Inc.
Amy Chan, 855-662-6732
investors@oncosec.com

KEYWORDS:   United States  North America  California

INDUSTRY KEYWORDS:

Chemtura Petroleum Additives Business Announces Price Increase for Calcium Sulfonate Complex Grease Products

PHILADELPHIA--(BUSINESS WIRE)-- The Petroleum Additives business of Chemtura Corporation (NYSE/Euronext: CHMT) is announcing a price increase on its calcium sulfonate complex grease (G-2000 series) products of 11 cents per kilogram effective Sept. 20, 2013, or as contracts allow. This price increase is due to recent raw material costs increases.

Petroleum Additives

Chemtura Petroleum Additives is a global and market-driven value innovator in supply of additives and finished lubricants for automotive and industrial applications. Additional information concerning the Petroleum Additives business is available at www.chemtura.com

Chemtura Corporation

Chemtura Corporation, with 2012 sales of $2.6 billion,⁽¹⁾ is a global manufacturer and marketer of specialty chemicals, agrochemicals and pool, spa and home care products. Additional information concerning Chemtura is available at www.chemtura.com.

⁽¹⁾ 2012 net sales of $2.6 billion reflects discontinued operations treatment for the sale of Chemtura's plastic antioxidants business.

Chemtura Corporation
Wayne Mackwood, +1-416-724-3653

KEYWORDS:   United States  Europe  North America  France  Pennsylvania

INDUSTRY KEYWORDS:

ICF International Awarded Two Contracts with the U.S. Environmental Protection Agency

Combined Value of Contracts Totals up to Approximately $31 million

FAIRFAX, Va.--(BUSINESS WIRE)-- ICF International (NAS: ICFI) , a leading provider of consulting services and technology solutions to government and commercial clients, has been awarded one new contract and one re-compete contract with the U.S. Environmental Protection Agency (EPA) to support the EPA's Environmental Services Assistance Team program in Region 3 and in Region 9. Combined, the contracts have a total value of up to approximately $31 million and both have terms of three base years, two option years, and two award term years.

ICF was awarded a new contract with the EPA Region 3 laboratory to provide technical, analytical, and quality assurance support. The contract has a value of up to approximately $11 million. Additionally, ICF won a re-compete contract with the EPA Region 9 laboratory to provide technical, analytical, and quality assurance support. The contract has a value of up to approximately $20 million.

Under these contracts, ICF International will support primarily the Superfund program across a range of activities, including laboratory analytical and quality assurance support, review of analytical data, support for the ambient air monitoring quality assurance program, and general laboratory support.

"ICF is very proud to have supported the EPA Region 9 laboratory for more than 20 years and now also to be supporting the EPA's Region 3 laboratory," said Mark Lee, vice president for ICF International. "We look forward to continuing our support of the EPA in meeting the challenging and changing analytical needs of the agency's programs."

For More Information

• ICF IT Solutions
• ICF Management Consulting

About ICF International

ICF International (NAS: ICFI) partners with government and commercial clients to deliver professional services and technology solutions in the energy, environment, and infrastructure; health, social programs, and consumer/financial; and public safety and defense markets. The firm combines passion for its work with industry expertise and innovative analytics to produce compelling results throughout the entire program lifecycle, from research and analysis through implementation and improvement. Since 1969, ICF has been serving government at all levels, major corporations, and multilateral institutions. More than 4,500 employees serve these clients from more than 60 offices worldwide. ICF's website is http://www.icfi.com.

Caution Concerning Forward-looking Statements

Statements that are not historical facts and involve known and unknown risks and uncertainties are "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Such statements may concern ICF's current expectations about its future results, plans, operations and prospects and involve certain risks, including those related to the government contracting industry generally; ICF's particular business, including its dependence on contracts with U.S. federal government agencies; and its ability to acquire and successfully integrate businesses. These and other factors that could cause ICF's actual results to differ from those indicated in forward-looking statements are included in the "Risk Factors" section of ICF's securities filings with the Securities and Exchange Commission. The forward-looking statements included herein are only made as of the date hereof, and ICF specifically disclaims any obligation to update these statements in the future.

ICF International
Erica Eriksdotter, +1-703-934-3668
erica.eriksdotter@icfi.com

KEYWORDS:   United States  North America  Virginia

INDUSTRY KEYWORDS:

Third Member of Leading Supermarket Group Adopts ReposiTrak™, the Industry Standard Food Safety Platform

Northeastern Wholesaler Initiates ReposiTrak for their Supply Chain

SALT LAKE CITY--(BUSINESS WIRE)-- ReposiTrak, a food safety solution provider backed by international food safety consultants Leavitt Partners and retail technology experts Park City Group (NYSE MKT: PCYG) today announced the successful initiation of the "on-boarding" process for the suppliers of the third member of ROFDA (Retailer Owned Food Distributors & Associates), the largest cooperative of independent food wholesalers in the U.S. The ReposiTrak system, which includes Document Management and Track & Trace, is now available to ROFDA's hundreds of retail locations in the northeast U.S.

"The continued adoption of the ReposiTrak food safety tracking and tracing platform by a third ROFDA wholesaler continues to enforce that food wholesalers today recognize the need for increased visibility to business relationships and the ability to track and trace products and their ingredients in the supply chain," said Rich McKeown, President of ReposiTrak.

Powered by Park City Group's technology, ReposiTrak helps manage regulatory, financial and brand risk associated with issues of food safety in the global food supply chain. ReposiTrak enables grocery warehouses, supermarkets, packaged goods manufacturers, food processing facilities, drug stores and drug manufacturers, as well as logistics partners, to track and trace products and components throughout the food, drug and dietary supplement supply chains. In addition, the technology addresses the market need of receiving, storing, sharing, and maintaining regulatory documentation all in one convenient location. ReposiTrak reduces risk in the supply chain by identifying backward chaining sources and forward chaining recipients of products in near real time.

Glendale, Alabama -based ROFDA is a cooperative established in 1962 to promote and support the retailer-owned distribution segment of the food industry. ROFDA members represent 20% of the supermarket industry and nearly 50,000 suppliers.

About Retailer Owned Food Distributors & Associates (ROFDA)

In 1962, a few cooperative food distributors from around the southeast formed an organization known as the, "Southeastern Food Cooperative Association," (SFCA). Over the years, growth from outside the southeast occurred as cooperatives recognized the numerous advantages of participating in a cooperative only environment. Due to the new geographic locations of its members and the changing demands of the retailer owned segment of the food industry, the name, Southeastern Food Cooperative Association, did not appropriately identify its members. So in 1988, a name change of the association was approved by its Board of Directors, and thus the new name, Retailer Owned Food Distributors & Associates (ROFDA), emerged. The mission of ROFDA is to promote and support the retailer-owned distribution segment of the food industry with value added programs and services, all in furtherance of servicing independent retail grocers located throughout America.

About ReposiTrak

ReposiTrak is collaboration between Leavitt Partners and Park City Group. ReposiTrak provides food retailers and suppliers with a robust solution to help protect their brands and remain in compliance with rapidly evolving regulations in the Food Safety Modernization Act. Powered by Park City Group's technology, ReposiTrak is an internet-based solution that enables all participants in the farm-to-table supply chain to easily manage tracking and traceability requirements as products move between trading partners. More information is available at www.repositrak.com.

About Park City Group

Park City Group (NYSE MKT: PCYG) is a Software-as-a-Service ("SaaS") provider that brings unique visibility to the consumer goods supply chain, delivering actionable information that ensures product is on the shelf when the consumer expects it as well as providing food safety tracking information. The Company's service increases customers' sales and profitability while enabling lower inventory levels and ensuring regulatory compliance for both retailers and their suppliers. Through a process known as Consumer Driven Sales Optimization™, Park City Group helps its customers turn information into cash and increased sales, using the largest scan based platform in the world. Scan based trading provides retail trading partners with a distinct competitive advantage through scan sales that provides store level visibility and sets the supply chain in motion. And since it is scan based, it can be used in a Direct Store Delivery (DSD) or warehouse setting.

About Leavitt Partners

Leavitt Partners advises clients in the health care and food safety sectors. The firm applies its experience, knowledge and a network of global relationships to serve our clients. As a food safety and health care intelligence business we provide the best available window to the future of American health care. More information is available at www.leavittpartners.com.

RAM Communications
Ronald Margulis, 908-272-3930
ron@rampr.com

KEYWORDS:   United States  North America  Alabama  Utah

INDUSTRY KEYWORDS:

Xcel Energy to Participate in Panel Discussions at Wolfe Research Power & Gas Leaders Conference

MINNEAPOLIS--(BUSINESS WIRE)-- On Tuesday, September 24, Xcel Energy's (NYS: XEL) Chairman, President & CEO, Ben Fowke, will speak to the financial community at the Wolfe Research Power and Gas Leaders Conference in New York as follows:

8:45 a.m. Eastern - "Regulated Growth Stories"

Interested investors can access the live audio webcast and presentation materials at:

http://www.xcelenergy.com
Click on: Investor Relations

The presentation material will be archived on our website.

This information is not given in connection with any sale or offer for sale or offer to buy any security.

Xcel Energy
Paul Johnson, 612-215-4535
Vice President Investor Relations and Business Development
or
News media inquiries:
Xcel Energy media relations, 612-215-5300
Xcel Energy Internet address: www.xcelenergy.com

KEYWORDS:   United States  North America  Minnesota  New York

INDUSTRY KEYWORDS:

Sigma-Tau PharmaSource, Inc. and Aradigm Corporation Sign Manufacturing Agreement for the Clinical and Commercial Supply of Pulmaquin

INDIANAPOLIS & HAYWARD, Calif.--(BUSINESS WIRE)-- Sigma-Tau PharmaSource, Inc. (a wholly owned subsidiary of Sigma-Tau Pharmaceuticals Inc.), a biopharmaceutical contract manufacturer specializing in complex injectable formulations, including liposomal drug delivery technology and PEGylation, and Aradigm Corporation (OTC BB: ARDM.OB), an emerging specialty pharmaceutical company focused on the development and commercialization of drugs delivered by inhalation for the prevention and treatment of severe respiratory diseases, today announced that they have entered into a broad manufacturing services agreement whereby Sigma-Tau PharmaSource will provide Aradigm with clinical and commercial supplies of Pulmaquin®. Pulmaquin is Aradigm's proprietary formulation of inhaled ciprofloxacin for the treatment of severe respiratory diseases, including non-cystic fibrosis bronchiectasis (BE).

Under terms of the agreement, Sigma-Tau PharmaSource will manufacture all product for Aradigm's Phase 3 clinical studies, and will support Aradigm in the preparation of its submissions to regulatory authorities in pursuit of marketing approval for the product. Subsequent to market approval, Sigma-Tau PharmaSource will produce the product commercially for patients using Pulmaquin. Financial terms of the agreement were not disclosed.

BE is a chronic orphan condition characterized by abnormal dilatation of the bronchi and bronchioles often associated with chronic lung infection. The disease is frequently observed in patients with cystic fibrosis (CF). However, it also affects over 110,000 people without CF in the U.S. and elsewhere, and results from a cycle of inflammation, recurrent infection, and bronchial wall damage.

Commenting on today's news, Dave Lemus, Chief Executive Officer of Sigma-Tau Pharmaceuticals, noted, "We are delighted to be able to expand our partnership with Aradigm, as Pulmaquin enters Phase 3 trials and Aradigm pursues potential future commercialization of this promising therapeutic for its underserved patient population. Moreover, this latest manufacturing services agreement underscores the strong fit that this project has, with not only our very significant expertise in complex liposomal formulations, but also with the capabilities of our manufacturing facility in the wake of extensive upgrades recently made to the plant."

"Sigma-Tau PharmaSource and Aradigm have a long history of working together on multiple programs, including manufacture of our AERx® inhaler dosage forms and, importantly, all of our Phase 1 and Phase 2 clinical supplies of our inhaled ciprofloxacin formulations. We are therefore delighted to be entering this exciting new phase of our Pulmaquin development with them," said Igor Gonda, President and Chief Executive Officer of Aradigm.

About Sigma-Tau PharmaSource, Inc.

Sigma-Tau PharmaSource, Inc., a wholly owned subsidiary of Sigma Tau Pharmaceuticals, Inc., is located in Indianapolis, IN, on a 26 acre site, with a manufacturing facility of 56,000 sq. ft. in addition to a leased facility of 13,500 sq. ft. for warehousing and offices. The site manufactures the key products for Sigma-Tau Pharmaceuticals, Inc. (Oncaspar, Adagen, and Abelcet) and provides third party manufacturing services for customers, together serving global markets (US, Canada, Mexico, Brazil, Europe, Middle East, Africa). All products manufactured are sterile, aseptically filled vial products. The plant's focus for third party manufacturing is on small to medium scale liquid injectables, with particular emphasis on complex liposomal or pegylated formulations.

About Sigma-Tau Pharmaceuticals, Inc.

Sigma-Tau Pharmaceuticals, Inc. is a U.S.-based, wholly owned subsidiary of the Sigma-Tau Group, and is dedicated to the global development and commercialization of medicines for patients with rare diseases. Sigma-Tau Pharmaceuticals, Inc. is based in Gaithersburg, Maryland, and the company's marketed products are focused on cancer, kidney disease, gastrointestinal and genetic related disorders. The company also has clinical development programs focused on transplant, inflammation related disorders, hematological cancer, certain inherited genetic disorders, malaria, and other areas of unmet medical need. For more information about the Sigma-Tau Pharmaceuticals, Inc., visit www.sigmatau.com.

About Aradigm Corporation

Aradigm is an emerging specialty pharmaceutical company focused on the development and commercialization of drugs delivered by inhalation for the prevention and treatment of severe respiratory diseases. Aradigm has product candidates addressing the treatment of bronchiectasis, cystic fibrosis, inhalation tularemia and anthrax infections, and prevention of respiratory and other diseases in tobacco smokers through smoking cessation. More information about Aradigm can be found at www.aradigm.com.

Aradigm, the Aradigm Logo, Pulmaquin and AERx are registered trademarks of Aradigm Corporation.

Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20130916005063/en/

Contact for Sigma-Tau PharmaSource
Rx Communications Group, LLC
Paula Schwartz, 917-322-2216
Senior Vice President
or
Contact at Aradigm Corporation
Aradigm Corporation
Nancy Pecota, 510-265-8800
Chief Financial Officer

KEYWORDS:   United States  North America  California  Indiana

INDUSTRY KEYWORDS:

University of Phoenix Introduces Two New Information Technology Degree Programs

New programs offer concentrations in health care and mobile development

PHOENIX--(BUSINESS WIRE)-- University of Phoenix® today announced the introduction of two new information technology (IT) degree programs dedicated to providing the body of knowledge needed to attain certifications in the fields of health care and mobile development. The University's College of Information Systems and Technology has created the Bachelor of Science in Information Technology degree in Mobile Development (BSIT/MD) and Associate of Arts in Information Technology degree in Health Care IT (AAIT/HIT) programs for students seeking to enter and grow in these rapidly growing industries.

Information-related job growth in the health care field is expected to increase by 21 percent between 2010 and 2020, according to the Bureau of Labor Statistics. Likewise, the Bureau also reports that jobs for software developers, which include those developing mobile-specific applications, are expected to grow by 30 percent between 2010 and 2020; much faster than for other occupations. With these opportunities comes a need for educated workers familiar with the latest technology and systems.

"As the fields of health care and mobile communications continue to grow, so does the need for skilled, certified professionals who can meet the information and technology needs of these industries," said Dr. Bill Pepicello, University of Phoenix president. "The introduction of these new programs reinforces University of Phoenix's dedication to providing our students with courses and curriculum designed to meet the business challenges of today's ever-changing market."

The AAIT/HIT program provides a foundation of IT fundamentals, and is designed for students who are seeking a college degree and IT professionals seeking to obtain entry-level positions in health care IT. This program provides the knowledge needed in order for graduates to take the industry-recognized CompTIA Healthcare Technician (HIT) certification exam. The BSIT/MD program prepares students to design, develop and implement mobile applications in the leading mobile platforms, and provides a certificate in mobile development issued by University of Phoenix upon completion of the program.

"University of Phoenix is dedicated to providing employable education to meet today's business IT needs, and these new programs being launched expand on this mission," said Blair Smith, dean of University of Phoenix College of Information Systems and Technology. "Businesses continue to increase their demand for certified IT professionals, and these new programs can provide our students with the bridge between their current education and a meaningful career."

Maryland residents completing undergraduate degree programs will earn an emphasis, rather than a concentration in a particular area of study. For more information about these programs, along with all of University of Phoenix's IT degrees and certification programs, visit www.phoenix.edu/technology.

About the College of Information Systems and Technology

University of Phoenix College of Information Systems and Technology is a leader and advocate for the development and advancement of IT in global business operations. The College offers associate, bachelor's, master's and doctoral degree programs. Its Faculty Advisory Council, composed of experts and leaders in the field, ensures curriculum is on pace with national and international market demands. Providing innovative digital learning tools developed to suit all learning styles, the College focuses on building technical knowledge and its successful application to real-world business environments. For more information, visit www.phoenix.edu/technology.

About University of Phoenix

University of Phoenix is constantly innovating to help working adults move efficiently from education to careers in a rapidly changing world. Flexible schedules, relevant and engaging courses, and interactive learning can help students more effectively pursue career and personal aspirations, while balancing their busy lives. As a subsidiary of Apollo Group, Inc. (NAS: APOL) , University of Phoenix serves a diverse student population, offering associate, bachelor's, master's and doctoral degree programs from campuses and learning centers across the U.S., as well as online throughout the world. For more information, visit www.phoenix.edu.

University of Phoenix
Christopher Fielder, 847-285-2608
christopher.fielder@apollogrp.edu

KEYWORDS:   United States  North America  Arizona

INDUSTRY KEYWORDS:

PowerSecure Provides Innovative Combination of Solar and Distributed Generation Solutions to Sandy Grove Middle School

WAKE FOREST, N.C.--(BUSINESS WIRE)-- PowerSecure International, Inc. (NYS: POWR) , announced today that it has designed and installed the power systems for Sandy Grove Middle School (SGMS) in Lumber Bridge, NC, which opened for the 2013-2014 school year as one of the nation's first net positive energy schools.

The LEED platinum certified school, which produces more energy than it consumes, will utilize a 589 kW DC solar photovoltaic system, designed and installed by PowerSecure Solar. Additionally, a 600 kW generator from PowerSecure, which includes PowerSecure's custom controls and distributed generation solution, will enable demand response when the local utility, Lumbee River Electrical Cooperative, begins its anticipated demand response program in 2014.

"When we acquired our solar capabilities in 2012, we were looking to integrate solar with our industry-leading DG offering through microgrid, firm solar and other applications, and the project at Sandy Grove is a fantastic example of how these combined assets can deliver enhanced value to our customers," said Sidney Hinton, chief executive officer of PowerSecure.

SGMS is expected to serve as a model for new school design and is anticipated to save nearly $16 million in energy cost alone over the next 40 years. Combined with other operations and maintenance efficiencies, SGMS will save Hoke County, NC more than $35 million during that same period.

PowerSecure partnered with First Floor/SFL&A, the school developer and architect, Optima Engineering, the building engineer, and MetCon Inc., the general contractor, to develop this net positive energy school prototype, incorporating integrated distributed energy systems, geothermal and state of the art energy efficiency.

About PowerSecure

PowerSecure International, Inc. is a leading provider of utility and energy technologies to electric utilities, and their industrial, institutional and commercial customers. PowerSecure provides products and services in the areas of Interactive Distributed Generation ^® (IDG^®), energy efficiency and utility infrastructure. The company is a pioneer in developing IDG^® power systems with sophisticated smart grid capabilities, including the ability to 1) forecast electricity demand and electronically deploy the systems to deliver more efficient, and environmentally friendly, power at peak power times, 2) provide utilities with dedicated electric power generation capacity to utilize for demand response purposes and 3) provide customers with the most dependable standby power in the industry. Its proprietary distributed generation system designs utilize a range of technologies to deliver power, including renewables. The company's energy efficiency business develops energy efficient lighting technologies that improve the quality of light, including its proprietary EfficientLights^® LED lighting products for grocery, drug and convenience stores, and its SecureLite area light and PowerLite street lights for utilities and municipalities. PowerSecure also provides electric utilities with transmission and distribution infrastructure maintenance and construction services, and engineering and regulatory consulting services. Additional information is available at www.powersecure.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are all statements other than statements of historical facts, including but not limited to statements concerning the outlook for the company's future revenues, earnings, margins, cash resources and cash flow and other financial and operating information and data; the company's future business operations, strategies and prospects; the company's cost reduction plan; and all other statements concerning the plans, intentions, expectations, projections, hopes, beliefs, objectives, goals and strategies of management, including statements about other future financial and non-financial items, performance or events and about present and future products, services, technologies and businesses; and statements of assumptions underlying the foregoing.

Forward-looking statements are not guarantees of future performance or events and are subject to a number of known and unknown risks, uncertainties and other factors that are difficult to predict and could cause actual results to differ materially from those expressed, projected or implied by such forward-looking statements. Important risks, uncertainties and other factors include, but are not limited to, the on-going downturn, disruption and volatility in the economy, financial markets and business markets and the effects thereof on the company's markets and customers, the demand for its products and services, and the company's access to capital; the size, timing and terms of sales and orders, including the company's revenue backlog, and the risk of customers delaying, deferring or canceling purchase orders or making smaller purchases than expected; the potential adverse financial and reputational consequences that can result from safety risks and hazards such as accidents inherent in the company's operations; the impact of the company's recent acquisitions of the ESCO business, the Solais business, and the commercial and industrial solar business; the company's ability to reduce and control its costs and expenses; the timely and successful development, production and market acceptance of new and enhanced products, services and technologies of the company; the ability of the company to obtain adequate supplies of key components and materials of sufficient reliability and quality for its products and technologies on a timely and cost-effective basis and the effects of related warranty claims and disputes; the ability of the company to successfully expand its core distributed generation products and services, to successfully develop and achieve market acceptance of its new energy-related businesses, to successfully expand its recurring revenue projects, to manage its growth and to address the effects of any future changes in utility tariff structures and environmental requirements on its business solutions; the effects of competition; changes in customer and industry demand and preferences; the ability of the company to continue the growth and diversification of its customer base; the ability of the company to attract, retain, and motivate its executives and key personnel; changes in the energy industry in general and the electricity, oil, and natural gas markets in particular, including price levels; the effects of competition; the ability of the company to secure and maintain key contracts and relationships; the effects of pending and future litigation, claims and disputes; and other risks, uncertainties and other factors identified from time to time in its reports filed with or furnished to the Securities and Exchange Commission, including the company's most recent Annual Report on Form 10-K, as well as subsequently filed reports on Form 10-Q and Form 8-K, copies of which may be obtained by visiting the investor relations page of the company's website at www.powersecure.com or the SEC's website at www.sec.gov .

Accordingly, there is no assurance that the results expressed, projected or implied by any forward-looking statements will be achieved, and readers are cautioned not to place undue reliance on any forward-looking statements. The forward-looking statements in this press release speak only as of the date hereof and are based on the current plans, goals, objectives, strategies, intentions, expectations and assumptions of, and the information currently available to, management. The company assumes no duty or obligation to update or revise any forward-looking statements for any reason, whether as the result of changes in expectations, new information, future events, conditions or circumstances or otherwise.

PowerSecure International, Inc.
John Bluth, 919-453-2103

KEYWORDS:   United States  North America  North Carolina

INDUSTRY KEYWORDS:

More than Forty Percent of U.S. Consumers Willing to Switch Physicians to Gain Online Access to Electronic Medical Records, According to Accenture Survey

Majority of Patients Have Taken Ownership of Records by Self-Tracking Personal Health Information

ARLINGTON, Va.--(BUSINESS WIRE)-- Supporting the growing trend toward patient engagement, a recent Accenture (NYS: ACN) survey found that many U.S. consumers (41 percent) would be willing to switch doctors to gain online access to their own electronic medical records (EMR). The survey, of more than 9,000 people in nine countries, shows that only about a third of U.S. consumers (36 percent) currently have full access to their EMR, but more than half (57 percent) have taken ownership of their record by self-tracking their personal health information, including their health history (37 percent), physical activity (34 percent) and health indicators (33 percent), such as blood pressure and weight.

"The rise of Meaningful Use mandates and a growing trend of self-care among consumers is shifting the role of an EMR from a mere clinical repository to a platform for shared decision-making among consumers and doctors," said Kaveh Safavi M.D., J.D., managing director of Accenture's North America health business. "Just as consumers can self-manage most other aspects of their lives, they expect to take greater ownership of their medical care, and they are willing to switch to doctors who share their values and are willing to provide access to consumer records."

Roughly four out of five consumers (84 percent) surveyed believe they should have full access to their electronic medical record while only a third of physicians (36 percent) share this belief. In contrast, the majority of U.S. doctors (65 percent) say patients should only have limited access to their records and that is what most individuals (63 percent) say they currently have.

"When consumers are part of the record-keeping process, it can increase their understanding of conditions, improve motivation and serve as a clear differentiator for clinical care," added Safavi.

Methodology

Accenture conducted an online survey of 9,015 adults ages 18+ to assess consumer perceptions of their medical providers' electronic capabilities across nine countries: Australia, Brazil, Canada, England, France, Germany, Singapore, Spain and the United States. The survey, which included 1,000 U.S. consumers, was fielded by Harris Interactive in July 2013. Where relevant, the survey compares select findings from the Accenture Doctors Survey to compare the doctor and consumer responses.

Learn more about Accenture's Insight Driven Health, Accenture Connected Health Services and Delivering Public Service for the Future.

About Accenture

Accenture is a global management consulting, technology services and outsourcing company, with more than 266,000 people serving clients in more than 120 countries. Combining unparalleled experience, comprehensive capabilities across all industries and business functions, and extensive research on the world's most successful companies, Accenture collaborates with clients to help them become high-performance businesses and governments. The company generated net revenues of US$27.9 billion for the fiscal year ended Aug. 31, 2012. Its home page is www.accenture.com.

Through Accenture Connected Health Services, the company helps health systems improve collaboration and decision-making, while lowering costs, by delivering healthcare IT solutions that enable consumer-centric care delivery and improve operating models. Services combine extensive business and clinical practices with a full range of healthcare IT capabilities, including health information exchanges, electronic health records, population analytics, mobility and telehealth platforms.

Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20130916005300/en/

Accenture
Jenn Francis, + 630 338 6426
jennifer.francis@accenture.com

KEYWORDS:   United States  North America  Virginia

INDUSTRY KEYWORDS:

Textron AirLand Introduces Scorpion ISR/Strike Aircraft

Commercially developed, affordable platform to satisfy broad range of U.S. and partner nations defense needs.

PROVIDENCE, R.I.--(BUSINESS WIRE)-- Textron AirLand, LLC, a joint venture between Textron Inc. (NYS: TXT) and AirLand Enterprises, LLC, today unveiled its Scorpion prototype, a versatile Intelligence, Surveillance and Reconnaissance (ISR)/Strike aircraft platform. The aircraft was introduced during a press conference at the Air Force Association Air & Space Conference and Technology Exposition in National Harbor, Maryland.

Scorpion ISR/Strike twin-jet tactical aircraft developed by Textron AirLand. (Photo: Business Wire)

The demonstration aircraft is now in test phase, with first flight scheduled to occur before the end of this year—a rapid schedule by any measure of military jet development. Textron Chairman and CEO Scott Donnelly said, "We began development of the Scorpion in January 2012 with the objective to design, build and fly the world's most affordable tactical jet aircraft capable of performing lower-threat battlefield and homeland security missions." Donnelly continued, "We relied on commercial best practices to develop a tactical jet platform with flexibility and capabilities found only in far more costly aircraft."

The Scorpion is designed to accommodate the increasingly stringent budget constraints of the U.S. Department of Defense and U.S. partner nations. The Scorpion's design is well matched to the Air National Guard's missions such as irregular warfare, border patrol, maritime surveillance, emergency relief, counter-narcotics and air defense operations. While Scorpion's lower acquisition price is an advantage, an equally important benefit is the lower cost of operation over the aircraft's full lifecycle. Combining ease of maintenance and globally-available commercial components, the Scorpion can significantly lower the customer's total cost of ownership.

F. Whitten Peters, former U.S. Secretary of the Air Force, an investor in and advisor to AirLand Enterprises, LLC, commented, "With its industry-leading capabilities in commercial aircraft and defense systems design and manufacturing, Textron was a natural partner to bring the vision of an affordable tactical military jet to fruition." He added, "In an impressively short time, the joint venture has designed and built a capable and mission-ready aircraft with no up-front government funding. We believe Scorpion will fill a critical price and performance gap in the tactical military aircraft market."

For a closer look at the Scorpion and its mission capabilities, please visit www.ScorpionJet.com.

Downloadable images of the aircraft are available in the Scorpion Media Gallery.

About Textron

Textron is a multi-industry company that leverages its global network of aircraft, defense, industrial and finance businesses to provide customers with innovative solutions and services. Textron is known around the world for its powerful brands such as Bell Helicopter, Cessna Aircraft Company, Jacobsen, Kautex, Lycoming, E-Z-GO, Greenlee and Textron Systems. More information is available at www.textron.com.

About Textron AirLand, LLC

Textron AirLand, LLC is a joint venture between Textron Inc. and AirLand Enterprises, LLC with the purpose of designing and manufacturing an affordable, capable jet platform based on commercially available technologies and processes for the tactical military jet aviation market. More information about our initial aircraft is available at www.ScorpionJet.com.

About AirLand Enterprises, LLC

AirLand Enterprises, LLC was formed by a group of experienced aerospace and defense executives dedicated to bringing an effective, low-cost, ISR/Strike jet to domestic and international military markets, replacing aging aircraft and complimenting high-end multi-role fighters.

Certain statements in this press release are forward-looking statements which may project revenues or describe strategies, goals, outlook or other non-historical matters; these statements speak only as of the date on which they are made, and we undertake no obligation to update or revise any forward-looking statements. These statements are subject to known and unknown risks, uncertainties, and other factors that may cause our actual results to differ materially from those expressed or implied by such forward-looking statements, including, but not limited to, the efficacy of research and development investments to develop new products or unanticipated expenses in connection with the launching of significant new products or programs; the timing of our new product launches or certifications of our new aircraft products; our ability to keep pace with our competitors in the introduction of new products and upgrades with features and technologies desired by our customers; changing priorities or reductions in the U.S. Government defense budget, including those related to military operations in foreign countries; changes in foreign military funding priorities or budget constraints and determinations, or changes in government regulations or policies on the export and import of military and commercial products; and volatility in the global economy or changes in worldwide political conditions that adversely impact demand for our products; performance issues with key suppliers or subcontractors.

Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20130916005176/en/

Investor Contact:
Textron
Doug Wilburne, 401-457-2288
or
Justin Bourdon, 401-457-2288
or
Media Contact:
Textron
David Sylvestre, 401-457-2362

KEYWORDS:   United States  North America  Rhode Island

INDUSTRY KEYWORDS:

Montezuma Completes 2013 Drilling at Miranda's Red Canyon Gold Project

VANCOUVER, British Columbia--(BUSINESS WIRE)-- Miranda Gold Corp. ("Miranda") (TSX-V: MAD) is pleased to announce its exploration funding partner at Red Canyon, Montezuma Mines Inc. ("Montezuma"), a wholly owned subsidiary of CMQ Resources Inc. (TSX-V:NV), has completed its 2013 drill campaign at Red Canyon. Montezuma drilled three reverse circulation ("RC") holes in the Wall structural corridor for a total of 2,170 ft (661.4 m).

The three RC holes tested portions of the northwest-trending Wall structural corridor, interpreted from gravity and resistivity surveys, in the Wall (two holes) and Ice (one hole) target areas. The corridor is approximately 1,500 ft (460 m) wide, at least 13,000 ft (4,000 m) long, and includes all or portions of three of the nine identified exploration targets at Red Canyon. Montezuma's 2009 core hole MR09-05C intersected 39 ft of 0.281 oz Au/ton (11.9 m of 9.64 g Au/t) in the vicinity of interpreted Wall corridor structures in the Ice target area. Montezuma's three 2013 RC holes probed the margins of the Wall corridor for intersections of inferred bounding faults with favorable limestone stratigraphy. All holes intersected calcareous siltstone to limestone and anomalous gold ranging up to 0.051 g Au/t.

Montezuma remains confident that Red Canyon contains opportunity for a significant gold discovery. After evaluating the accumulated project data, Montezuma will propose a work plan for 2014.

Since 2009, Montezuma performed geologic mapping, revised stratigraphic interpretations, completed soil and rock-chip geochemical surveys, and contracted CSAMT resistivity, ground magnetic, and gravity geophysical surveys. To date, Montezuma drilled a total of 35 RC and three core holes for a total of 35,212 ft (10,732.6 m). Montezuma conducts its drilling under the Bureau of Land Management-approved Red Canyon Plan of Operations that permits up to 125 acres (50 hectares) of total disturbance.

Project Details

The Red Canyon project is in Eureka County, Nevada, includes 254 unpatented lode mining claims (7.9 sq mi / 20.6 sq km) on the Battle Mountain-Eureka Trend, and adjoins U.S. Gold's Tonkin Springs property to the west. The project covers an erosional "window" through the upper plate of the Roberts Mountains Thrust that exposes hydrothermally altered and brecciated lower-plate carbonate rocks that are age equivalent to the rocks hosting Barrick Gold's Cortez Hills gold deposit.

All data disclosed in this press release have been reviewed by Vice President of Exploration, Joe Hebert, a Qualified Person as defined by National Instrument 43-101.

Corporate Profile

Miranda Gold Corp. is a gold exploration company active in Nevada, Alaska and Colombia and whose emphasis is on generating gold exploration projects with world-class discovery potential. Miranda performs its own grass-roots exploration and then employs a joint venture business model on its projects in order to maximize exposure to discovery while minimizing exploration risk. Miranda has ongoing partnerships with, Montezuma Mines Inc., Prism Resources Inc., Ramelius Resources Ltd., and Red Eagle Mining Corporation.

ON BEHALF OF THE BOARD

"Kenneth Cunningham"

Kenneth Cunningham
President and CEO

For more information visit the Company's web site at www.mirandagold.com or contact Joe Hebert, Vice President, Exploration at 775-738-1877.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

U.S. investors are cautioned that mineral deposits on adjacent properties are not indicative of mineral deposits on our properties. We advise U.S. investors that the SEC's mining guidelines strictly prohibit information of this type in documents filed with the SEC.

This news release contains forward-looking statements that are based on the Company's current expectations and estimates. Forward-looking statements are frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate", "suggest", "indicate" and other similar words or statements that certain events or conditions "may" or "will" occur. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual events or results to differ materially from estimated or anticipated events or results implied or expressed in such forward-looking statements. Such factors include, among others: the actual results of current exploration activities; conclusions of economic evaluations; changes in project parameters as plans to continue to be refined; possible variations in ore grade or recovery rates; accidents, labour disputes and other risks of the mining industry; delays in obtaining governmental approvals or financing; and fluctuations in metal prices. There may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. Any forward-looking statement speaks only as of the date on which it is made and, except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or results or otherwise. Forward-looking statements are not guarantees of future performance and accordingly undue reliance should not be put on such statements due to the inherent uncertainty therein.

Miranda Gold Corp.
Joe Hebert, 775-738-1877
Vice President, Exploration

KEYWORDS:   United States  North America  Canada  Nevada

INDUSTRY KEYWORDS:

There's a Coach in Every Watch — Garmin ^® Forerunner ^® 620 and 220 with Color Display

OLATHE, Kan.--(BUSINESS WIRE)-- Garmin International Inc., a unit of Garmin Ltd. (NAS: GRMN) , the global leader in satellite navigation, today announced the Forerunner 620 and Forerunner 220 GPS running watches - two of the lightest, thinnest, most advanced offerings for runners from Garmin, and the next best thing to having a personal running coach. The Forerunner 620 offers advanced features like recovery advisor, race predictor and VO2 max estimate to help runners train smarter and achieve new race goals. When used with the NEW HRM-Run™ monitor¹, the 620 also provides feedback on running form. For indoor training, like on a treadmill, the 620 and 220's built-in accelerometer tracks distance and pace, so runners don't need a separate sensor. Both models boast Garmin's unique one-inch Chroma™ color display to easily interpret data. To see the Forerunner 620 and 220 in action, go to www.garmin.com/ForerunnerCoach.

Garmin Forerunner 620 and 220 (Photo: Business Wire)

"Whether running indoors or out, Forerunner 620 and 220 will change the way runners look at training," said Dan Bartel, Garmin vice president of worldwide sales. "Advanced features in the 620 such as recovery advisor, VO2 max estimate, race predictor and stats on running economy, combined with connected features and training plan options found in both the 620 and 220, make these watches must haves for runners of all levels. To keep runners motivated the watches also notice if runners hit any personal records on that run, like their fastest mile, 5k, 10k, half or full marathon or their longest run to date."

Regardless of a runner's experience, motivation, or how far or fast they go, they likely want to know how they can improve and objectively measure their fitness. Forerunner 620 does just that by estimating runners' VO2 max, which is a good indicator of athletic capability. Previously, the only way to accurately obtain VO2 max was by paying for a lab test. When used with a heart rate monitor, the 620 incorporates several pieces of data, like running speed, beats per minute and heart rate variability, into an advanced algorithm to estimate runners' VO2 max. The number itself indicates the maximum volume of oxygen a runner can consume per minute, per kilogram of body weight at their max performance. Theoretically, the more oxygen runners can use during high-level exercise, the more energy they can produce. A color gauge on the watch display shows how a runner's VO2 max data compares to other individuals of their gender and age range. Based on the VO2 max estimate, the 620 can predict a runner's race time for several distances. This can give runners a time target for their next race, assuming they've completed proper training.

When wearing HRM-Run, Forerunner 620's NEW recovery advisor and recovery check take the guesswork out when it comes to planning recovery time between hard workouts. Just like a coach, it learns the runner and their physiology based on heart rate data, so it factors this against their last workout and then shows how much time before they are fully recovered and ready for their next hard running workout. Color-coding on the high-resolution Chroma display gauge makes it easy to interpret — green, of course, means they are good to go. When runners see red on the display and a recovery time of more than 3 days, they might consider taking a rest day or just doing a light recovery run. HRM-Run also has an accelerometer in the module that measures torso movement in order to calculate 3 different running metrics:

• Cadence — the number of steps per minute. It displays the total steps (right and left combined)
• Vertical oscillation — the bounce in runners' running motion. It displays the vertical motion of a runners' torso, measured in centimeters.
• Ground contact time — the amount of time in each step that you spend on the ground while running, measured in milliseconds.

"The Forerunner 620 is a watch that runners have been waiting for," said Dr. Jack Daniels, famed running coach, author and exercise physiologist. "Being able to monitor runners' running dynamics and receive real-time feedback in a watch is a huge step in running innovation."

Thanks to their Bluetooth^® Smart wireless upload capabilities, Forerunner 620 and 220 can send runners' run data to the Garmin online community, Garmin Connect™, without being connected to a computer. It can transfer the data through the Garmin Connect Mobile app on their compatible smartphone. Additional connected features include live tracking, which allows runners' friends and fans to follow along and see their stats in real-time. Runners must have their phone paired with their 620 or 220 throughout the run to use the LiveTrack feature. Victories, goals achieved and successes can be shared on runners' social media sites by posting updates through the Garmin Connect Mobile app. And, for real-time coaching as they run, both the 620 and 220 are compatible with free training plans at Garmin Connect. Runners can also set up their Forerunner 620 to work with one or more Wi-Fi hot spots, such as their home and office networks, to automatically sync with Garmin Connect when in range. Syncing with Garmin Connect on a regular basis not only ensures the upload of runners' data, it also sends the next seven days worth of satellite data, to Forerunner 620 and 220, to ensure the fastest possible satellite acquisition — no more standing and waiting, and seeing runners with their wrists to the sky while waiting for a signal.

With the growing popularity of the run/walk training method in the distance running community (example: a runner runs for five minutes, walks for one minute and repeats for the duration of the course), Garmin has included a run/walk alert. This alert allows Forerunner 620 and 220's other features, such as Auto Lap and Auto Pause, to remain active during a run/walk session.

Both Forerunner 620 and 220 are water-resistant to 50m and can stand up to much more than rain, sweat and splashes. The Forerunner 620 has a touchscreen display responsive enough that it can be operated with running gloves, while the 220 is operated with easy to push buttons. Both models have rechargeable batteries lasting up to six weeks in watch mode and up to 10 hours in training mode.

Forerunner 620 is available in blue/black and white/orange, while Forerunner 220 is available in black/red and white/violet and are expected to ship fall 2013 and have suggested retail prices of $399.99/$449.99 (HRM-Run Bundle) and $249.99/$299.99 (Heart Rate Bundle) respectively. Forerunner 620 and Forerunner 220 are the latest solutions from Garmin's expanding fitness segment, which focuses on developing technologies and innovations to enhance users' lives and promotes healthy and active lifestyles. Whether it's running, cycling, or other athletic pursuits, Garmin fitness devices are becoming essential tools for athletes both amateur and elite. For more about features, pricing and availability, as well as information about Garmin's other fitness products and services, go to www.garmin.com/intosports, www.garmin.blogs.com and http://twitter.com/garmin.

About Garmin International Inc.

Garmin International Inc. is a subsidiary of Garmin Ltd. (NAS: GRMN) , the global leader in satellite navigation. Since 1989, this group of companies has designed, manufactured, marketed and sold navigation, communication and information devices and applications - most of which are enabled by GPS technology. Garmin's products serve automotive, mobile, wireless, outdoor recreation, marine, aviation, and OEM applications. Garmin Ltd. is incorporated in Switzerland, and its principal subsidiaries are located in the United States, Taiwan and the United Kingdom. For more information, visit Garmin's virtual pressroom at www.garmin.com/pressroom or contact the Media Relations department at 913-397-8200. Garmin and Vector are registered trademarks and ANT+ and Garmin Connect are trademarks of Garmin Ltd. or its subsidiaries.

The Bluetooth^® word mark is a registered trademark owned by Bluetooth SIG, Inc. and any use of such mark by Garmin is under license. All other brands, product names, company names, trademarks and service marks are the properties of their respective owners. All rights reserved.

Notice on Forward-Looking Statements:

This release includes forward-looking statements regarding Garmin Ltd. and its business. Such statements are based on management's current expectations. The forward-looking events and circumstances discussed in this release may not occur and actual results could differ materially as a result of known and unknown risk factors and uncertainties affecting Garmin, including, but not limited to, the risk factors listed in the Annual Report on Form 10-K for the year ended December 29, 2012, filed by Garmin with the Securities and Exchange Commission (Commission file number 0-31983). A copy of such Form 10-K is available at www.garmin.com/aboutGarmin/invRelations/finReports.html. No forward-looking statement can be guaranteed. Forward-looking statements speak only as of the date on which they are made and Garmin undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

¹Included with some models, sold separately on others.

Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20130916005495/en/

Garmin International Inc.
Justin McCarthy, 913-397-8200
media.relations@garmin.com

KEYWORDS:   United States  North America  Kansas

INDUSTRY KEYWORDS:

Cision Announces Adjustments to Prior Year Retained Earnings

STOCKHOLM--(BUSINESS WIRE)-- Regulatory News:

In the second quarter interim report 2013, Cision (STO:CSN) announced that its Board of Directors had instructed a thorough review of the US organization's balance sheet as previous deficiencies in reconciliation procedures had been identified. The outcome of the review is that adjustments to the group's prior year retained earnings of SEK 60 million are required, of which SEK 48 million net of a positive tax impact relates to incorrect revenue recognition over the previous five years. As a part of the review Cision also assessed the carrying value of its fixed assets. Cision found that entries dating back more than five years also needed to be adjusted by SEK 12 million to reflect the appropriate carrying value for fixed assets. The adjustments identified do not affect 2013 trading results and do not have any cash effect.

The required adjustments were the result of having relatively complex systems and ineffective controls in connection with the handling of deferred revenue in the Cision US business. Cision has calculated and verified the corrections to deferred revenue and associated control accounts and has identified the necessary adjustments to control procedures to ensure correct handling in future.

During the past twelve months significant changes to the Cision US finance leadership team have taken place including a new CFO, a new Controller, a new Finance Manager, and a re-organisation of the receivables team. In addition a Financial Planning Analyst was hired and Cision appointed new auditors, KPMG, in April 2013. These changes have all enabled improvements to financial control procedures including more robust reconciliation procedures which have been subjected to sampling and testing by KPMG. The Cision Group finance function has also made changes to follow-up routines to improve the detection and explanation of unusual variances.

The attached table below shows the effect of the adjustments to the Cision Group balance sheets for 2011 and 2012. Cision's third quarter interim statement will be published on October 23, 2013 when further details will be provided for comparison purposes.

Table included in attached PDF.

http://mb.cision.com/Main/329/9469062/162081.pdf

The information provided herein is such that Cision AB (publ) is obligated to disclose pursuant to the Swedish Securities Markets Act (SFS 2007:528) and/or the Swedish Financial Instruments Trading Act (SFS 1991:980). The information was submitted for publication at 08:30 AM CEST on September 19, 2013.

Cision is a leading provider of cloud-based PR software, services and tools for the marketing and public relations industry. Marketing and PR professionals use our products to help manage all aspects of their brands - from identifying key media and influencers to connecting with audiences; monitoring traditional and social media; and analyzing outcomes. Journalists, bloggers, and other influencers use Cision's tools to research story ideas, track trends, and maintain their public profiles. Cision is present in Europe, North America and Asia, is quoted on the Nordic Exchange with revenue of approx. SEK 1.0 billion in 2012. For more information, visit www.cision.com.

This information was brought to you by Cision http://news.cision.com

Cision AB (publ)
Peter Granat, President and CEO
Tosh Bruce-Morgan, Group CFO
Phone: +46 (0)8 507 410 11
e-mail: investorrelations@cision.com

KEYWORDS:   Europe  Sweden

INDUSTRY KEYWORDS: